Related Experiment Videos
Treprostinil for pulmonary hypertension.
Jean-Luc Vachiéry1, Robert Naeije
1Department of Cardiology, Erasme University Hospital, Brussels, Belgium. Jean-Luc.Vachiery@ulb.ac.be
Expert Review of Cardiovascular Therapy
|May 21, 2004
Summary
Treprostinil, a prostacyclin analog, improves outcomes for pulmonary arterial hypertension patients. While generally safe, infusion site pain can be a limiting side effect for some.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Pulmonary Medicine
Background:
- Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis.
- Prostacyclin analogs are a key treatment modality for PAH.
- Treprostinil offers a stable, long-acting prostacyclin analog option.
Purpose of the Study:
- To evaluate the efficacy and safety of treprostinil in patients with pulmonary arterial hypertension.
- To compare treprostinil therapy with existing treatments for PAH.
Main Methods:
- Continuous subcutaneous infusion of treprostinil using a portable delivery system.
- Monitoring of clinical status, functional class, exercise capacity, and quality of life.
- Assessment of side effects, including infusion site pain and prostacyclin-related symptoms.
Main Results:
- Treprostinil demonstrated improvements in clinical state, functional class, exercise capacity, and quality of life.
- Common side effects like facial flush and headache were manageable with dose adjustments.
- Infusion site pain occurred in approximately 10% of patients, potentially limiting treatment.
Conclusions:
- Treprostinil is an effective treatment for pulmonary arterial hypertension, offering significant patient benefits.
- The drug possesses an excellent safety profile, comparable to intravenous epoprostenol.
- Treprostinil is a valuable option within current pulmonary arterial hypertension treatment guidelines.